HK1130255A1 - Indole derivatives as s1p1 receptor agonists - Google Patents

Indole derivatives as s1p1 receptor agonists

Info

Publication number
HK1130255A1
HK1130255A1 HK09109205.3A HK09109205A HK1130255A1 HK 1130255 A1 HK1130255 A1 HK 1130255A1 HK 09109205 A HK09109205 A HK 09109205A HK 1130255 A1 HK1130255 A1 HK 1130255A1
Authority
HK
Hong Kong
Prior art keywords
receptor agonists
indole derivatives
indole
derivatives
agonists
Prior art date
Application number
HK09109205.3A
Other languages
English (en)
Inventor
Ahmed Mahmood
James Myatt
David Norton
Dean Andrew Rivers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1130255(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to HK10107189.4A priority Critical patent/HK1140761A1/xx
Publication of HK1130255A1 publication Critical patent/HK1130255A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
HK09109205.3A 2006-12-21 2009-10-06 Indole derivatives as s1p1 receptor agonists HK1130255A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK10107189.4A HK1140761A1 (en) 2006-12-21 2009-10-06 Indole derivatives as s1p1 receptor agonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds
PCT/EP2007/064185 WO2008074821A1 (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
HK1130255A1 true HK1130255A1 (en) 2009-12-24

Family

ID=39283563

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10107189.4A HK1140761A1 (en) 2006-12-21 2009-10-06 Indole derivatives as s1p1 receptor agonists
HK09109205.3A HK1130255A1 (en) 2006-12-21 2009-10-06 Indole derivatives as s1p1 receptor agonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10107189.4A HK1140761A1 (en) 2006-12-21 2009-10-06 Indole derivatives as s1p1 receptor agonists

Country Status (33)

Country Link
US (1) US8101775B2 (no)
EP (2) EP2206710B1 (no)
JP (1) JP5309034B2 (no)
KR (1) KR101495927B1 (no)
CN (1) CN103012390B (no)
AR (1) AR064452A1 (no)
AT (1) ATE509927T1 (no)
AU (1) AU2007336224B2 (no)
BR (1) BRPI0721127A2 (no)
CA (1) CA2673468C (no)
CL (1) CL2007003755A1 (no)
CR (2) CR10922A (no)
CY (2) CY1111702T1 (no)
DK (2) DK2091949T3 (no)
DO (1) DOP2009000133A (no)
EA (1) EA017406B1 (no)
ES (1) ES2389879T3 (no)
HK (2) HK1140761A1 (no)
HR (2) HRP20110456T1 (no)
IL (1) IL199187A (no)
JO (1) JO2701B1 (no)
MA (1) MA30999B1 (no)
MX (1) MX2009006882A (no)
MY (2) MY148470A (no)
NO (1) NO20092385L (no)
NZ (1) NZ577387A (no)
PE (2) PE20121076A1 (no)
PL (2) PL2206710T3 (no)
PT (2) PT2206710E (no)
SG (1) SG177914A1 (no)
SI (2) SI2206710T1 (no)
TW (1) TWI393564B (no)
WO (1) WO2008074821A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2003132T3 (pl) 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CL2008001099A1 (es) * 2007-04-19 2008-10-24 Glaxo Group Ltd Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
PL2913326T3 (pl) 2008-05-14 2020-11-16 The Scripps Research Institute Nowe modulatory receptorów fosforanu sfingozyny
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
US20100029729A1 (en) * 2008-06-20 2010-02-04 Jose Luis Castro Pineiro Compounds
SG10201503157PA (en) * 2008-07-23 2015-06-29 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
AU2009274569C1 (en) 2008-07-23 2015-06-25 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl) acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
BRPI0917923B1 (pt) * 2008-08-27 2022-04-05 Arena Pharmaceuticals Inc Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição
EP2376484B1 (en) * 2008-12-18 2015-04-22 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
EP3868377A1 (en) 2009-11-13 2021-08-25 Receptos Llc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
JP2013514280A (ja) * 2009-12-18 2013-04-25 グラクソ グループ リミテッド スフィンゴシン１−リン酸１（ｓ１ｐ１）受容体アゴニストとして使用するためのオキサジアゾール置換インダゾール誘導体
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
CN102884064B (zh) * 2010-03-03 2016-01-13 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
JP5735634B2 (ja) 2010-04-23 2015-06-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
UA113507C2 (xx) 2011-02-07 2017-02-10 Модулятори s1p
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN108349891B (zh) 2015-06-22 2022-04-05 艾尼纳制药公司 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
JP6883882B2 (ja) * 2016-07-22 2021-06-09 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｓ１ｐ１アゴニスト及びその応用
KR102408814B1 (ko) * 2016-09-29 2022-06-14 리셉토스 엘엘씨 루푸스를 치료하기 위한 화합물 및 방법
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
EP4051250A1 (en) 2019-10-31 2022-09-07 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
EP4103549A1 (en) * 2020-02-11 2022-12-21 Syngenta Crop Protection AG Pesticidally active cyclic amine compounds
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US7199142B2 (en) 2002-06-17 2007-04-03 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
CA2524867A1 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US20070043014A1 (en) 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
WO2006090817A1 (ja) 2005-02-25 2006-08-31 Ono Pharmaceutical Co., Ltd. インドール化合物およびその用途
WO2006100633A1 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS
AU2006240789B2 (en) 2005-04-22 2010-03-04 Daiichi Sankyo Company, Limited Heterocyclic compound
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
JP2009506046A (ja) 2005-08-23 2009-02-12 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制剤化合物および組成物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
PL2003132T3 (pl) * 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
SI2069336T1 (sl) 2006-09-07 2013-03-29 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot imunomodulirna sredstva
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CL2008001099A1 (es) 2007-04-19 2008-10-24 Glaxo Group Ltd Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.

Also Published As

Publication number Publication date
EP2091949A1 (en) 2009-08-26
AR064452A1 (es) 2009-04-01
DK2206710T3 (da) 2012-08-27
AU2007336224A1 (en) 2008-06-26
HRP20120685T1 (hr) 2012-09-30
JO2701B1 (en) 2013-03-03
KR101495927B1 (ko) 2015-02-25
TW200843736A (en) 2008-11-16
EA017406B1 (ru) 2012-12-28
PL2091949T3 (pl) 2011-10-31
SI2206710T1 (sl) 2012-10-30
CR10922A (es) 2009-08-12
IL199187A0 (en) 2010-03-28
PE20121076A1 (es) 2012-09-05
CA2673468A1 (en) 2008-06-26
JP2010513397A (ja) 2010-04-30
AU2007336224B2 (en) 2013-01-10
PT2206710E (pt) 2012-09-10
TWI393564B (zh) 2013-04-21
CN103012390B (zh) 2015-08-26
KR20090092290A (ko) 2009-08-31
EP2206710A1 (en) 2010-07-14
NO20092385L (no) 2009-08-24
BRPI0721127A2 (pt) 2014-03-11
PL2206710T3 (pl) 2012-11-30
EA200970612A1 (ru) 2009-10-30
SI2091949T1 (sl) 2011-08-31
JP5309034B2 (ja) 2013-10-09
PE20081398A1 (es) 2008-11-19
CY1113131T1 (el) 2016-04-13
PT2091949E (pt) 2011-07-13
MX2009006882A (es) 2009-07-03
MY148470A (en) 2013-04-30
EP2206710B1 (en) 2012-07-04
CL2007003755A1 (es) 2008-08-22
US20100113796A1 (en) 2010-05-06
MY156822A (en) 2016-03-31
ES2389879T3 (es) 2012-11-02
CN103012390A (zh) 2013-04-03
IL199187A (en) 2015-04-30
NZ577387A (en) 2012-01-12
MA30999B1 (fr) 2009-12-01
WO2008074821A1 (en) 2008-06-26
HK1140761A1 (en) 2010-10-22
DK2091949T3 (da) 2011-07-18
HRP20110456T1 (hr) 2011-07-31
DOP2009000133A (es) 2009-08-15
US8101775B2 (en) 2012-01-24
CY1111702T1 (el) 2015-10-07
CA2673468C (en) 2015-06-02
CR20140316A (es) 2014-08-20
EP2091949B1 (en) 2011-05-18
SG177914A1 (en) 2012-02-28
ATE509927T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
HK1140761A1 (en) Indole derivatives as s1p1 receptor agonists
IL192657A (en) Theophenic history as 1edg / 1p1s receptor agonists
IL197395A0 (en) Thiophene derivatives as s1p1/edg1 receptor agonists
AP2007004067A0 (en) Oxyindole derivatives as 5HT4 receptor agonists
IL193042A0 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists
IL200911A0 (en) Amino-pyridine derivatives as s1p1/edg1 receptor agonists
IL198931A0 (en) Benzamide derivatives as ep4 receptor agonists
ZA200709087B (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
ZA200709086B (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
PT2003132E (pt) Derivados de oxadiazole como agonistas dos s1p1
EP2049520A4 (en) indole compounds
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
HK1149762A1 (en) Substituted indole derivatives
HK1110980A1 (en) Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
ZA200905265B (en) Indole derivatives
ZA200900843B (en) Indole compounds
ZA200903829B (en) Indole derivatives as S1P1 receptor agonists
ZA200709829B (en) Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151219